CA-ANDERSEN-GLOBAL
Andersen — the leader in tax, valuation, financial advisory, and related consulting services — and The University of San Francisco (USF) have extended their partnership to create The Enterprise MBA program, in which eligible Andersen employees can earn an MBA in three to five years, fully-funded by Andersen on behalf of its employees. Modeled after the USF Masagung Graduate School of Management’s rigorous Part-Time MBA offering, the new program offers a standard MBA curriculum with courses tailored to address the specific professional development needs of Andersen employees in today’s complex, global business environment.
The new program is available to employees of Andersen member firms and collaborating firms, starting with U.S. employees and rolling out worldwide in 2023. Full- and part-time Andersen employees from senior associates to partners — regardless of tenure — are eligible for the program. Participating students must take three to four courses per year, delivered online and asynchronously, to complete the program requirements in five years. The first cohort of nearly 50 students started the pilot program in June 2022. USF welcomed 14 new Andersen students to the program in November 2022 and is targeting another 25-50 for January.
“Andersen strives to be the best professional services firm in the world and this new program is consistent with our dedication to continuous professional development and stewardship,” said Mark Vorsatz, CEO of Andersen. “To be the best in our industry, we have to attract and retain the best talent — that’s why we’re so committed to investing in our people. Working closely with the innovative educators at USF, we’ve built a customized program that reflects and enhances the work Andersen employees do on behalf of our clients every day. As the program grows, we expect it to be a unifying employee experience across our practice areas and global offices.”
Andersen’s offering is unique in the degree to which the firm was involved in course development, and the fact that the program is global in nature, fully funded by the firm, and does not have any kind of clawback, should employees enrolled in the program choose to leave the firm.
“Andersen’s culture is what keeps us together and what sets us apart,” continued Vorsatz. “Our investment in our people at all stages is just one component of how we are building and maintaining that culture.”
A Customized MBA to Meet Andersen’s Business Needs
Andersen and USF’s Masagung Graduate School of Management worked together to create a customized program, including content, delivery, modality, structure and timing, and even jointly creating a special elective class on the importance of company culture. In addition, in certain classes, Andersen senior staff can serve as adjunct professors to aid in instruction. Three trimesters of courses are offered each year: from early January to mid-to-late February; from early May to the end of August; and from early-November to mid-December. Given Andersen’s tax-centered business, program courses are offered outside of the busy tax seasons between March 1 and April 15 and between September 1 and October 15.
“This a truly unique and collaborative program and the close partnership between USF and Andersen sets a new standard for the future of corporate education,” said Otgo Erhemjamts, Dean of the School of Management at USF. “It demonstrates how educational institutions and companies can come together to address skill gaps and prepare organizations and their personnel for the rapidly evolving business world.”
Andersen and USF started their collaboration in 2014 when the organizations first partnered to provide Andersen personnel the opportunity to earn a Master of Laws in Taxation (LLM) or a Master of Legal Studies in Taxation (MLST) from the University of San Francisco School of Law. To date, more than 120 employees from 11 countries have graduated from those programs.
"The University of San Francisco, founded by the Jesuits in 1855, has long worked with the business community in and beyond the City to strengthen their talent pool,” stated USF President Rev. Paul J. Fitzgerald, S.J. “Our work with Andersen has been a terrific iteration of this work. The alignment of our cultures makes this excellent teaching/learning experience possible. We are especially grateful to Mr. Vorsatz for envisioning this dynamic partnership."
Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 13,000 professionals worldwide and a presence in over 390 locations through its member firms and collaborating firms.
About the USF School of Management
Founded in 1925, University of San Francisco’s School of Management is on the forefront of educating the next generation of conscious, mindful business leaders. Each year those students join the over 40,000 School of Management alumni around the world to create ethical and innovative change in the private, public, and non-profit management sectors. The School of Management is accredited by the Western Association of Schools and Colleges Senior College and University Commission (WSCUC) and the Association to Advance Collegiate Schools of Business (AACSB).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
